Marco Rusnati

Title: Marco Rusnati: Innovator in Biopharmaceuticals

Introduction

Marco Rusnati is a notable inventor based in Bussero, Italy. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of peptides that interact with growth factors. His work has implications for treating various diseases linked to altered growth factor activity.

Latest Patents

Marco Rusnati holds 2 patents that showcase his innovative approach. His latest patents include "FGF2-binding peptides and uses thereof," which describes synthetic peptides designed from the N-terminal region of PTX. These peptides are capable of binding to FGF and inhibiting its pro-angiogenic activity both in vitro and in vivo, without adversely affecting innate immunity. Another significant patent is the use of the long pentraxin PTX3 for treating diseases caused by altered activation of the growth factor FGF-2. This patent outlines the preparation of a medicament that inhibits the biological activity of FGF-2, which is useful for preventing and treating related diseases.

Career Highlights

Throughout his career, Marco Rusnati has worked with prominent companies in the pharmaceutical industry, including Tecnogen S.p.a. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Marco has collaborated with esteemed colleagues such as Marco Presta and Maura Camozzi. These partnerships have fostered a collaborative environment that enhances the research and development of new biopharmaceuticals.

Conclusion

Marco Rusnati's contributions to the field of biopharmaceuticals through his innovative patents and collaborations highlight his role as a key inventor. His work continues to pave the way for advancements in treatments for diseases related to growth factor activity.